November 24, 2020 17:33 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Strict action should be taken against officials guilty for hooch problem: BSP chief Mayawati | Supreme Court nixes ex-BSF jawan's plea challenging PM Modi's election from Varanasi | Cyclone Nivar: PM Modi assures support from Centre to Tamil Nadu, Puduchurry | India records 37,975 new COVID-19 cases, 480 deaths | 'We don't see as Hindu and Muslim but two grown up individuals': Allahabad HC on inter-religion marriage case
COVID-19 Vaccine For Children Not Expected This Year - Head of Gamaleya Reseach Institute COVID-19

COVID-19 Vaccine For Children Not Expected This Year - Head of Gamaleya Reseach Institute

India Blooms News Service | @indiablooms | 04 Aug 2020, 08:38 am

Moscow/Sputnik: The coronavirus vaccine will not be available for children in Russia yet, it has to go through a full cycle of trials on adults first, the director of the Gamaleya Scientific Research Institute of Epidemiology and Microbiology, Alexander Gintsburg, told Sputnik.

"I really hope that the vaccine will work for children, but according to Russian law, a vaccine can only be tested on children after it has gone through the full cycle of tests on adults, so when the third phase of trials is over, we will be allowed to conduct the 18- tests," Gintsburg explained.

Vadim Tarasov, Director of the Sechenov Institute for Translational Medicine and Biotechnology told Sputnik that before using the vaccine on children, preclinical trials are usually carried out on immature animals, after which a decision is made on the use of the vaccine on children.

"It is too early to talk about using the vaccine on children, they are not a [coronavirus] risk group," Tarasov told Sputnik.

The Russian Direct Investment Fund (RDIF) expects Russia's first vaccine against COVID-19 to be registered within 10 days, RDIF CEO Kirill Dmitriev said on Monday. According to Dmitriev, Russia's monthly production of the vaccine could total 10 million by the end of the year.